Spero Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Spero Therapeutics CEO'su Sath Shukla, Aug2023 tarihinde atandı, in görev süresi 1.25 yıldır. in toplam yıllık tazminatı $ 2.02M olup, şirket hissesi ve opsiyonları dahil olmak üzere 25.9% maaş ve 74.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.068% ine doğrudan sahiptir ve bu hisseler € 41.57K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 10.5 yıldır.

Anahtar bilgiler

Sath Shukla

İcra Kurulu Başkanı

US$2.0m

Toplam tazminat

CEO maaş yüzdesi	25.9%
CEO görev süresi	1.3yrs
CEO sahipliği	0.07%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	10.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Sath Shukla'un ücretlendirmesi Spero Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$4m
Jun 30 2024	n/a	n/a	US$17m
Mar 31 2024	n/a	n/a	US$23m
Dec 31 2023	US$2m	US$524k	US$23m
Sep 30 2023	n/a	n/a	-US$2m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$2m	US$478k	-US$46m
Sep 30 2022	n/a	n/a	-US$102m
Jun 30 2022	n/a	n/a	-US$113m
Mar 31 2022	n/a	n/a	-US$103m
Dec 31 2021	US$2m	US$441k	-US$90m

Tazminat ve Piyasa: Sath 'nin toplam tazminatı ($USD 2.02M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 471.55K ).

Tazminat ve Kazançlar: Sath 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Sath Shukla (51 yo)

1.3yrs

Görev süresi

US$2,024,647

Tazminat

Mr. Satyavrat Shukla, also known as Sath, C.F.A., has been President, Chief Executive Officer and Director at Spero Therapeutics, Inc. since August 1, 2023. He had been the Chief Financial Officer of Spero...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ankit Mahadevia	Co-Founder & Chairman of the Board	11.2yrs	US$2.39m	0.43% € 260.1k
Satyavrat Shukla	President	1.3yrs	US$2.02m	0.068% € 41.6k
Timothy Keutzer	Chief Operating Officer	1.8yrs	US$1.44m	0.12% € 75.3k
Esther Rajavelu	CFO, Chief Business Officer & Treasurer	1.3yrs	Veri yok	0.70% € 422.5k
James Brady	Chief Human Resource Officer	3yrs	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: 2HA 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ankit Mahadevia	Co-Founder & Chairman of the Board	11.2yrs	US$2.39m	0.43% € 260.1k
Satyavrat Shukla	President	1.3yrs	US$2.02m	0.068% € 41.6k
Frank Thomas	Independent Director	7.3yrs	US$88.83k	0.028% € 16.7k
Milind Deshpande	Independent Director	10.8yrs	US$105.70k	0.058% € 35.0k
Eric Gordon	Scientific Advisors	10.5yrs	Veri yok	Veri yok
George Drusano	Clinical Advisor	10.5yrs	Veri yok	Veri yok
Steven Gilman	Scientific Advisor	no data	Veri yok	Veri yok
Patrick V. J. Vink	Lead Independent Director	9.2yrs	US$93.19k	0.028% € 16.7k
Gordon Archer	Clinical Advisor	10.5yrs	Veri yok	Veri yok
David Livermore	Scientific Advisor	no data	Veri yok	Veri yok
Paul Ambrose	Clinical Advisor	10.5yrs	Veri yok	Veri yok
Cynthia Smith	Independent Director	5.7yrs	US$73.20k	0.028% € 16.7k

10.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2HA 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.5 yıldır).

Spero Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

Co-Founder & Chairman of the Board recently sold €81k worth of stock

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023

Recent updates

Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.061 loss in 3Q 2023)

Investor sentiment improves as stock rises 17%

Spero Therapeutics, Inc. Announces SPR720 Phase 2a Interim Results

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.33 loss per share (vs US$0.23 loss in 2Q 2023)

Spero Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.25 loss in 1Q 2023)

Spero Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

New major risk - Revenue and earnings growth

Spero Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: EPS: US$0.43 (vs US$1.24 loss in FY 2022)

Spero Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New minor risk - Profitability

Co-Founder & Chairman of the Board recently sold €81k worth of stock

Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.061 loss per share (vs US$0.33 loss in 3Q 2022)

Spero Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

New major risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.87 loss in 2Q 2022)

Spero Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings released: US$0.25 loss per share (vs US$1.01 loss in 1Q 2022)

Spero Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$1.24 loss per share (vs US$2.91 loss in FY 2021)

Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023

Insufficient new directors

Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.70 loss in 3Q 2021)

Insufficient new directors

Spero Therapeutics, Inc. announced that it has received $8.999973 million in funding from GSK plc

Spero Therapeutics to Present Data at IDWeek 2022

Spero Therapeutics, Inc. announced that it expects to receive $8.999973 million in funding from GSK plc

Spero Therapeutics Announces Appointment of Kamal Hamed as Chief Medical Officer

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Second quarter 2022 earnings released: US$0.87 loss per share (vs US$0.63 loss in 2Q 2021)

Spero Therapeutics, Inc., Annual General Meeting, Sep 15, 2022

The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of A Class Action Lawsuit

Spero Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Its New Drug Application

Pomerantz Law Firm Announces the Filing of Class Action Lawsuit Against Spero Therapeutics, Inc

First quarter 2022 earnings released: US$1.01 loss per share (vs US$0.66 loss in 1Q 2021)

Spero Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline

Insufficient new directors

Full year 2021 earnings released: US$2.91 loss per share (vs US$3.52 loss in FY 2020)

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206

Spero Therapeutics Receives Up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients

Spero Therapeutics, Inc. Announces Lifting of FDA Clinical Trial Hold on SPR720

Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem Hbr for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.70 loss per share (vs US$0.86 loss in 3Q 2020)

Insufficient new directors

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.85 loss in 2Q 2020)

Spero Therapeutics, Inc. announced that it has received $39.994552 million in funding from Pfizer Inc.

Spero Therapeutics, Inc. Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of Spr206

Spero Therapeutics, Inc. Wins Funding of $2.09 Million, with the Potential for Up to an Additional $21.3 Million over 5 Years, from the National Institute of Allergy and Infectious Diseases

First quarter 2021 earnings released: US$0.66 loss per share (vs US$1.22 loss in 1Q 2020)

Full year 2020 earnings released: US$3.52 loss per share (vs US$3.36 loss in FY 2019)

Revenue misses expectations

New 90-day high: €19.00

Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

Spero Therapeutics Announces Issuance of Allowance for A U.S. Patent Covering Lead Candidate Tebipenem HBr